

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**BRISTOL-MYERS SQUIBB CO**

2. Address:

655 15TH STREET, NW, #300, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country): HOLLAND

4. Contact Name: RICHARD THOMPSON

Telephone: 2027838618

E-mail (optional): dick.thompson@bms.com

Senate ID #: 7053-12

House ID #:

7. Client Name: ☒ Self

## TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

## INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): \_\_\_\_\_

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 2,980,000.00

### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☒ **Method A.** Reporting amounts using LDA definitions only  
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Lobbied against an amendment to remove language from the MMA prohibiting IHS from interfacing in negotiations for the drug benefit. H.R. 5384, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2007. Lobbied to ensure safety of prescription drugs. H.R. 5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program. H.R. 5122, National Defense Authorization Act for FY2007, Lobbied to ensure safety and access to prescription drugs. H.Res.100, Continuing Resolutions for 2007 Appropriations, Lobbied to ensure adequate funding of healthcare programs. H.Con.Res.376, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2008 through 2011.

17. House(s) of Congress and Federal agencies contacted:

Agriculture, Dept of (USDA)  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL  
Covered Official Position (if applicable): N/A  
Name: CHURCH, LANE  
Covered Official Position (if applicable): N/A  
Name: PERNIE, CHRIS  
Covered Official Position (if applicable): N/A  
Name: THOMPSON, RICHARD  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BRISTOL-MYERS SQUIBB CO Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

S.2300, Federal Food Drug & Cosmetic Act, Lobbied to preserve exclusivity of innovative prescription drugs. H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs. H.R.5672, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2007, Lobbied to maintain the ability of the U.S. Trade Representative to negotiate intellectual property issues.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL

Covered Official Position (if applicable): N/A

Name: THOMPSON, RICHARD

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Lobbied to prevent provisions adverse to prescription drug approval process. H.R. 5647, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2007, Lobbied for increased funding for AIDS Drug Assistance Program. H.R. 328, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R. 700, Pharmaceutical Market Access Act of 2005, Lobbied to ensure safety of prescription drugs. H.R. 870, Federal Food, Drug and Cosmetic Act, Lobbied to ensure safety of prescription drugs. H.R. 898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to ensure access to medical devices and DME services. H.R. 6143, Ryan White Care Act Reauthorization, Lobbied to ensure safe access to prescription drugs. S. 1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. S. 2300, Lower Priced Drugs Act of 2006, Lobbied to preserve incentives for R&D for pediatric populations. S. 3558, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. S. 3582, to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, Lobbied to ensure the orderly transition of drugs from "innovation" to "generic" status. S. 3650, Helping Fill the Medicare Rx Gap Act, Lobbied to ensure safe access to prescription drugs. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children. S. Res 556, Lobbied to raise awareness of P.A.D. and for passage of the bill. H. Res 982, Lobbied to raise awareness of P.A.D. and for passage of the bill. H. Con. Res. 130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R. 2090, Food and Drug Administration Improvement Act of 2005.

17. House(s) of Congress and Federal agencies contacted:  
HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL  
Covered Official Position (if applicable): N/A  
Name: CHURCH, LANE  
Covered Official Position (if applicable): N/A  
Name: PERNIE, CHRIS  
Covered Official Position (if applicable): N/A  
Name: WARR, DAVID  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.3650, The Helping to Fill the Medicare Rx Gap Act, Lobbied for final passage of the bill. H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs.

17. House(s) of Congress and Federal agencies contacted:  
HOUSE OF REPRESENTATIVES  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL  
Covered Official Position (if applicable): N/A  
Name: CHURCH, LANE  
Covered Official Position (if applicable): N/A  
Name: PERNIE, CHRIS  
Covered Official Position (if applicable): N/A  
Name: RYAN, JOHN  
Covered Official Position (if applicable): N/A  
Name: THOMPSON, RICHARD  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BRISTOL-MYERS SQUIBB CO Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied again signing a discharge petition to bring this bill to a floor vote. H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding. H.R.4939, Emergency Supplemental Appropriations Act of Defense, the Global War on Terror, and Hurricane Recovery of 2006, Lobbied to preserve the market based Medicare Part D Rx drug Benefit. H.R.5704, Access to Medicare Imaging Act, Lobbied for passage of the bill, which would provide for a budget neutral two-year moratorium on Medicare payment reductions for imaging services. H.Con.Res.373, Establishing the congressional budget for the United States Government for fiscal year 2007, Lobbied to preserve the Medicare Part D drug benefit.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL

Covered Official Position (if applicable): N/A

Name: CHURCH, LANE

Covered Official Position (if applicable): N/A

Name: PERNIE, CHRIS

Covered Official Position (if applicable): N/A

Name: THOMPSON, RICHARD

Covered Official Position (if applicable): N/A

Name: WARR, DAVID

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BRISTOL-MYERS SQUIBB CO Client Name: Self

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

S.4026, Technical Tax Corrections Act of 2006, lobbied to amend the IRS Section 170 definition of income purposes of charitable contributions. H.R.6111, Tax Relief Extension Reconciliation Act of 2006, Lobbied to extend the research and development tax credit. H.R.6264, Technical Tax Corrections Act of 2006, lobbied to amend the IRS Section 170 definition of income purposes of charitable deductions.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: RYAN, JOHN

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: BRISTOL-MYERS SQUIBB CO Client Name: Self

### LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R.3025, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: CAROZZA, MICHAEL

Covered Official Position (if applicable): N/A

Name: PERNIE, CHRIS

Covered Official Position (if applicable): N/A

Name: WARR, DAVID

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 12, 2007

Printed Name and Title: RICHARD L. THOMPSON, SENIOR VICE PRESIDENT OF POLI -